Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC
Release Date:
Interview with Charu Aggarwal, MD, and Lova Sun, MD, authors of Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint Inhibitor–Based Therapy in Patients With Advanced Non–Small-Cell Lung Cancer
Association Between KRAS Variant Status and Outcomes With First-line Immune Checkpoint–Based Therapy in Patients With Advanced NSCLC